It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical Information Request
Medical Information Request

 

 

Our commitment to
ongoing communication
on safety

A verified up-to-date global source of safety
information from clinical trials and
post-marketing experience with
ofatumumab for Healthcare Professionals

Website full content last update*:
December 2021

 

Latest Updates:  March 2022 

 

As of September 25, 2021, a total of approximately 2,560 patients with relapsing multiple sclerosis (RMS) received ofatumumab in clinical trials including the ongoing open-label extension and  there was approximately 4,713 patient-years post marketing experience1

Home_Page
Home button

Report an adverse event

 
References
1. Data on file. Periodic Safety Update Report (Cut-off date: 25 September, 2021). Novartis Pharma AG.
*Last update included exposure, Ig levels, PML, fatalities, COVID-19, pregnancy, pivotal trial, references and FAQ sections